Carmen Brace will join Florida cannabis industry leaders and medical professionals to present the results of the recent CME (Continuing Medical Education) certified Aclara Research study on cannabis patient and consumer usage of cannabis. Click here to register
Join us at the CFBN and Fifty Gazelles Innovation Breakfast to hear a panel of cannabis industry leaders discuss industry expansion and implications to the consumer goods industry. Hear leaders from Aclara Research, Cresco Labs, Grassroots Cannabis and Fluresh discuss their experiences working in the industry.
Carmen Brace will speak at the The NPD Group Annual Summit "Winning the Moment". She will address The Future of Cannabis and impact to NPD clients across food service, traditional retailers and consumer packaged goods companies.
Carmen Brace to speak at Marijuana for Medical Professionals with the Holistic Cannabis Academy on October 14th in Denver, Colorado. The team will focus on their study of consumers using cannabis and Cannabidiol (CBD) products to manage chronic symptoms, and the role of the holistic health care practitioner.
Carmen Brace joins a panel at the Hatchery, a food business incubator in Chicago, to discuss the business implications of cannabis-infused products on September 26, 2018.
The past few years have been quite eventful from macro, retail, and lifestyle perspectives. Healthcare uncertainty; new approaches to health and wellness; growing emphasis on natural products; and new shopper demands, expectations, and values have all been active drivers of change.
Advocates often say that legal marijuana has the potential to combat America's opioid crisis, but anti-pot groups are claiming just the opposite. In a recent letter sent to legislators in states with forms of legal marijuana, drug-prevention organization Drug Free America claims that pot use is associated with an increased risk of abusing prescription opioids and warns against using medical marijuana to treat opioid-use disorder.
Carmen Brace testified as an expert witness for the Illinois legislature, presenting the results of the Aclara Research Fall 2017 Study on the impact of cannabis on prescription drug and opioid usage.
When the day is done, my choice of a mellow relaxer usually comes out of a tallish green bottle. It's preferably named zinfandel, malbec or cabernet sauvignon, and definitely is on the full-bodied side, with more than a hint of a nose and absolutely tasty enough for some serious lip smacking.
This time the data comes from Illinois and New Mexico.
Aclara’s Newest Study Shows Correlation between Medical Cannabis Use among Patients and Decrease of Prescription Opioid Usage
In a new study conducted by Aclara Research, medical use of cannabis has once again been shown to be a successful substitute for dangerous addictive opioid painkillers for many patients in pain.
Carmen Brace joins Illinois medical professionals and dispensary owners to present the results of the Illinois Patient Experience study at the Lake County Canna Expo. Join us to learn more about your questions regarding medical cannabis.
Carmen joins a panel of colleagues in Michigan cannabis industry to discuss the experience of entrepreneurship as a consumer insights research professional, a woman and as a person of color.
he results of the largest and most comprehensive look at the impact of the Illinois Medical Cannabis Patient Experience Study – a statewide program that has examined patients since 2012 – shows the positive impact of medical cannabis among patients and the health care industry.
A study of patients in Illinois suggests that CBD products are nearly as popular as THC products, and that women are the driving force behind sales of the former. The Illinois Medical Cannabis Patient Experience Study – conducted by Aclara Research, a Chicago medical marijuana patient research firm – found that 47% of patients said they use CBD daily and 22% had no previous experience with marijuana before joining the state’s MMJ program.
A new research study conducted on patients enrolled in Illinois' pilot medical marijuana program has found that cannabis treatments have helped patients cut back on prescription drug use, or even quit entirely. Medical cannabis consulting firm Aclara Research recently released The Illinois Medical Cannabis Patient Experience Study, the first study on the effectiveness of the state's pilot MMJ program, which was launched in 2012.
Aclara Research, a leader in the development of patient and consumer insights within the medical cannabis industry, today released the results of The Illinois Medical Cannabis Patient Experience Study – the first of Illinois patients since the inception of the pilot program in 2012. The study is the largest and most comprehensive look at the impact of the statewide program, examining nearly 300 of the 18,000 Illinois residents registered.
CHICAGO, May 23, 2017 (GLOBE NEWSWIRE) -- Aclara Research, a leader in the development of patient and consumer insights within the medical cannabis industry, today released the results of The Illinois Medical Cannabis Patient Experience Study - the first of Illinois patients since the inception of the pilot program in 2012. The study is the largest and most comprehensive look at the impact of the statewide program, examining nearly 300 of the 18,000 Illinois residents registered.